July 1, 2016 / 6:11 AM / in a year

BRIEF-Valeant Pharmaceuticals announces new licensing arrangement for Brodalumab in Europe

July 1 (Reuters) - Valeant Pharmaceuticals International Inc :

* Valeant Pharmaceuticals announces new licensing arrangement for Brodalumab in Europe

* Says affiliate and Astrazeneca have amended Valeant's license for Brodalumab

* Amendment for Brodalumab to terminate Valeant's right to develop and commercialize Brodalumab in Europe

* Astrazeneca has entered into an agreement granting Leo Pharma exclusive rights to develop and commercialize Brodalumab in Europe

* Under terms of amended agreement, Valeant will continue to hold license to develop and commercialize Brodalumab in U.S

* As consideration for termination of European rights, Astrazeneca to pay to co an upfront payment and certain sales-based milestone payments

* As consideration for termination of European rights, one of pre-launch milestones payable by co to Astrazeneca under original license reduced

Source text for Eikon:

Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below